Surgical management of superficial bladder cancer (stages Ta/T1/CIS)

Semin Surg Oncol. 1997 Sep-Oct;13(5):328-34. doi: 10.1002/(sici)1098-2388(199709/10)13:5<328::aid-ssu6>3.0.co;2-f.

Abstract

Transurethral surgery is the primary treatment for patients with superficial bladder cancer. Either electrical or laser thermal destruction is used most often but there is no proven therapeutic benefit for one method over the other. Treatment failure is usually a consequence of new tumor occurrence rather than the failure to eradicate existing visible tumors. Adjuvant intravesical chemotherapy or immunotherapy improves results over surgery alone in most circumstances.

Publication types

  • Review

MeSH terms

  • Administration, Intravesical
  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / therapeutic use
  • Carcinoma in Situ / drug therapy
  • Carcinoma in Situ / pathology
  • Carcinoma in Situ / surgery
  • Carcinoma in Situ / therapy
  • Carcinoma, Transitional Cell / drug therapy
  • Carcinoma, Transitional Cell / pathology
  • Carcinoma, Transitional Cell / surgery
  • Carcinoma, Transitional Cell / therapy
  • Chemotherapy, Adjuvant
  • Electrocoagulation
  • Humans
  • Immunotherapy
  • Laser Coagulation
  • Laser Therapy
  • Neoplasm Recurrence, Local / pathology
  • Neoplasm Staging
  • Neoplasm, Residual
  • Treatment Failure
  • Urethra / surgery
  • Urinary Bladder Neoplasms / drug therapy
  • Urinary Bladder Neoplasms / pathology
  • Urinary Bladder Neoplasms / surgery*
  • Urinary Bladder Neoplasms / therapy

Substances

  • Antineoplastic Agents